StocksMedium•10 November 2026•
1 min read
Autolus Therapeutics Reports Mixed Q3 2026 Results with Revenue Beat
Key Facts
1Autolus Therapeutics reported a GAAP EPS loss of $0.21, missing analyst estimates by $0.03.
2The company's revenue reached $41.24M, beating expectations by $1.21M.
Autolus Therapeutics reported a GAAP EPS loss of $0.21 for the third quarter of 2026, missing analyst estimates by $0.03. Seeking Alpha reported that the company's revenue reached $41.24 million during the period, beating expectations by $1.21 million.
AUTL closed at $1.32 on November 9, 2026, with the stock trading between a low of $1.23 and a high of $1.35 during that session. These financial results for the period ending September 2026 reflect a mixed performance for the biotech firm.